An observational study in Influenza and Influenza -Like Illness, sponsored by Thong Nhat Hospital. Not yet recruiting at 2 sites in Vietnam. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Thong Nhat Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Influenza, Human with a site in Vietnam — 2 open to participants now, 2 under way, 1 of them phase 3. Influenza, Human · Vietnam.
Among the 18 studies in Influenza, Human with a site in Vietnam, this one is the only one that started in 2027, is one of 4 observational ones, and was the 18th registered.
2,361 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 18 studies in Influenza, Human with a site in Vietnam are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Vietnam, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Vietnam have not opened yet or have stopped. Only those recruiting at a site in Vietnam →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 2,298 is above the median of 397 across 334 observational studies indexed under Influenza, Human.
Median enrollment 278 across the 14 interventional studies, 535 across the 4 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Thong Nhat Hospital as lead sponsor.
Thong Nhat Hospital has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
1 of the studies in Influenza, Human with a site in Vietnam that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Influenza, Human with a site in Vietnam, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the clinical and economic effectiveness of influenza vaccination among adults aged 60 years and older in Ho Chi Minh City, Vietnam. It will compare influenza-related health outcomes and healthcare costs between older adults who receive influenza vaccination and those who do not.
This is a prospective observational cohort study with a control group. The study plans to enroll 2,298 participants, including 766 vaccinated and 1,532 unvaccinated older adults. Participants will be recruited at Thong Nhat Hospital and University Medical Center Ho Chi Minh City. Vaccination status will be determined by participants' vaccination history and decisions made independently of the study.
Participants will be followed for 12 months, with follow-up assessments every three months. The study will collect information on influenza, influenza-like illness, cardiovascular events, respiratory events, hospitalization, mortality, and direct medical costs related to influenza.
The study will compare the occurrence of clinical outcomes and direct medical costs between the two groups. It will also evaluate economic measures related to influenza vaccination, including avoided treatment costs, cost savings, and the benefit-cost ratio. The findings will be used to provide scientific evidence for developing influenza vaccination policy recommendations for older adults in Ho Chi Minh City.
Participants will be recruited using consecutive convenience sampling. Baseline information will be collected using standardized data collection forms, including demographic characteristics, medical history, underlying diseases, influenza vaccination status, and other relevant clinical information.
During follow-up, data will be collected through scheduled telephone contacts, community-based follow-up, and information obtained from healthcare facilities. Reported clinical events and healthcare utilization will be verified using available medical records and other relevant sources.
To address potential differences in baseline characteristics between the vaccinated and unvaccinated groups, the study will use statistical methods to control for confounding factors. Propensity score matching will be applied to improve comparability between the two groups. The clinical and economic effectiveness of influenza vaccination will be evaluated using the collected data.
The study population comprises adults aged 60 years or older residing in Ho Chi Minh City, Vietnam. Participants will be recruited from two cohorts: older adults receiving one dose of influenza vaccine at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at enrollment, and unvaccinated older adults attending outpatient clinics at these hospitals who have not received influenza vaccination within the preceding 12 months. Participants will be selected using consecutive convenience sampling and followed for 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Belonging to one of the following two groups:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 60 years or older who receive influenza vaccination at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City during the study period. The date of vaccination serves as the start of the 12-month follow-up period.
Biological: Influenza vaccine
Adults aged 60 years or older attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination during the 12 months preceding enrollment. The enrollment date serves as the start of the 12-month follow-up period.
Influenza vaccination received as part of routine healthcare, independently of the study. Vaccination is not assigned or administered by the research team as a study intervention. Participants who receive influenza vaccination are included in the vaccinated cohort and followed for 12 months.
Incidence of Confirmed Influenza
The proportion of participants with confirmed influenza during the 12-month follow-up period. Confirmed influenza is defined by a positive rapid influenza antigen test, a positive reverse transcription-polymerase chain reaction (RT-PCR) test, viral isolation, or a documented influenza diagnosis in the medical record, in accordance with the study protocol.
Time frame: During the 12-month follow-up period
Incidence of Influenza-like Illness
The proportion of participants experiencing influenza-like illness (ILI) during the 12-month follow-up period. ILI is defined as an acute respiratory illness characterized by fever (measured body temperature of at least 38°C or self-reported fever or chills) accompanied by cough and/or sore throat, as specified in the study protocol.
Time frame: During the 12-month follow-up period
Avoided Treatment Costs
The estimated total treatment costs avoided through influenza vaccination over the 12-month follow-up period. Avoided treatment costs are calculated as the difference in mean treatment costs between the unvaccinated and vaccinated groups, multiplied by the number of vaccinated participants. Costs are expressed in Vietnamese dong (VND).
Time frame: Over the 12-month follow-up period
Net Cost Savings
Net cost savings associated with influenza vaccination over the 12-month follow-up period, calculated as the total estimated treatment costs avoided minus the total vaccination costs, in accordance with the study protocol. Net cost savings are expressed in Vietnamese dong (VND).
Time frame: Over the 12-month follow-up period
Benefit-Cost Ratio
The benefit-cost ratio of influenza vaccination over the 12-month follow-up period, calculated by dividing the total estimated treatment costs avoided by the total vaccination costs, as specified in the study protocol. The benefit-cost ratio is expressed as a dimensionless ratio.
Time frame: Over the 12-month follow-up period
Incidence of Respiratory Events
The proportion of participants experiencing respiratory events during the 12-month follow-up period. Respiratory events include bronchitis, pneumonia, acute exacerbations of chronic obstructive pulmonary disease, and acute exacerbations of asthma, as defined in the study protocol.
Time frame: During the 12-month follow-up period
Incidence of Cardiovascular Events
The proportion of participants experiencing cardiovascular events during the 12-month follow-up period. Cardiovascular events include acute myocardial infarction, acute stroke, and acute heart failure, as defined in the study protocol.
Time frame: During the 12-month follow-up period
Incidence of Influenza-Related Hospitalization
The proportion of participants hospitalized during the 12-month follow-up period due to influenza, influenza-related conditions, or complications of influenza, as defined in the study protocol.
Time frame: During the 12-month follow-up period
Influenza-Related Mortality
The proportion of participants who die during the 12-month follow-up period due to influenza, influenza-related causes, or complications of influenza, as defined in the study protocol.
Time frame: During the 12-month follow-up period
Total Direct Medical Costs
The total actual direct medical costs incurred during the 12-month follow-up period for the management of study-related clinical events. Costs are calculated by summing the actual medical expenditures associated with all relevant treatment episodes during follow-up and are expressed in Vietnamese dong (VND).
Time frame: Over the 12-month follow-up period
Total Medical Costs Based on Health Insurance Rates
The total medical costs associated with study-related clinical events during the 12-month follow-up period, calculated using the reimbursement rates specified by the Vietnamese health insurance system. Costs are summed across relevant treatment episodes and expressed in Vietnamese dong (VND).
Time frame: Over the 12-month follow-up period
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for May 2028, 16 months later.
Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 16 months is below that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.